No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

Blood. 2018 Jan 25;131(4):468-471. doi: 10.1182/blood-2017-08-802157. Epub 2017 Dec 11.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aminoglycosides / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Clinical Trials as Topic
  • Gemtuzumab
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Polymorphism, Single Nucleotide*
  • Sialic Acid Binding Ig-like Lectin 3 / genetics*
  • Treatment Outcome
  • Young Adult

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • CD33 protein, human
  • Sialic Acid Binding Ig-like Lectin 3
  • Gemtuzumab

Associated data

  • ISRCTN/ISRCTN17161961
  • ISRCTN/ISRCTN55675535